Weekly shot shows promise for Long-Term growth hormone replacement
Disease control
Completed
This study tested a once-weekly growth hormone injection (lonapegsomatropin) in 220 adults with growth hormone deficiency who had completed a prior trial. The main goal was to check long-term safety and side effects over 52 weeks. Researchers also measured changes in body fat and…
Phase: PHASE3 • Sponsor: Ascendis Pharma Endocrinology Division A/S • Aim: Disease control
Last updated May 14, 2026 12:04 UTC